MedTrace Logo

Registry For Patients Treated With BeneFix In Usual Care Setting In Germany

NCT00714415 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2018-10-25

Study results available
· View outcomes & findings →

Summary

The purpose of this observational study is to describe the incidence of adverse events among patients treated with BeneFix® in usual health care settings in Germany.

Conditions

  • Hemophilia B

Interventions

DRUG

BeneFIX

Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714415 on ClinicalTrials.gov